January 23, 2026
Women Don’t Regret Embryo Testing Before IVF, Study Reveals
A Northwestern University study confirms women aged 35+ don’t regret pre-IVF embryo genetic testing (PGT-A). The research validates doctors’ recommendations, showing the procedure helps avoid treatment delays and miscarriage risks by identifying chromosomal abnormalities.
Key Takeaways
PGT-A Testing for Women Over 35: Why Doctors Recommend It
Physicians like Dr. Daniel Skora advocate pre-IVF genetic testing (PGT-A) for women aged 35+ to improve decision-making. This testing reduces the risk of implanting chromosomally abnormal embryos, which can cause miscarriage or prolonged treatment cycles.
How Embryo Genetic Testing Reduces IVF Delays and Miscarriage Risks
The study highlights that PGT-A testing avoids unnecessary delays in IVF for women over 40. By identifying abnormal embryos early, patients can focus on transferring viable embryos, minimizing emotional and financial setbacks from failed transfers.
Northwestern University Study Validates Pre-IVF Genetic Screening Benefits
Research from Northwestern University confirms long-term patient satisfaction with pre-IVF genetic testing. Participants reported no regret over undergoing PGT-A, emphasizing its role in empowering informed reproductive choices.
PGT-A Explained: Chromosomal Abnormality Detection in IVF Embryos
Preimplantation genetic testing for aneuploidy (PGT-A) screens embryos for chromosomal abnormalities like trisomy 21. This testing is critical for older women, as age-related chromosomal errors increase miscarriage risks.
Why Age 40+ Patients Benefit Most From Pre-IVF Embryo Testing
Women over 40 face higher risks of chromosomally abnormal embryos due to declining egg quality. PGT-A testing directly addresses this by prioritizing embryos with the highest implantation potential, reducing treatment cycles and emotional stress.
Source: Read full article